What are the initial dosages of Lantus (insulin glargine) and Humalog (insulin lispro) for a 94.8-pound patient to improve Hemoglobin A1C (HbA1c) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a 94.8-pound patient, I recommend starting Lantus (insulin glargine) at 10 units once daily and Humalog (insulin lispro) at 4 units before meals to improve HbA1c levels. This recommendation is based on the guidelines provided by the American Diabetes Association, which suggest initiating basal insulin therapy with 10 units or 0.1 to 0.2 units/kg of body weight per day 1. For a 94.8-pound (43 kg) patient, the calculated dose would be approximately 4.3 to 8.6 units, but starting with 10 units is a safe and simple approach as suggested by the guidelines.

Key Considerations

  • The patient's weight is used to calculate the initial dose of Lantus, with the guideline suggesting 0.1 to 0.2 units/kg of body weight per day 1.
  • Humalog, being a rapid-acting insulin analogue, is preferred for premeal insulin dosing due to its quick onset of action, with a recommended starting dose of 4 U per meal or 0.1 U/kg per meal 1.
  • It is essential to monitor blood glucose levels at least 4 times daily (before meals and at bedtime) and adjust the insulin doses based on the patterns observed over the first 1-2 weeks.
  • The patient should be educated on recognizing hypoglycemia symptoms (such as sweating, shakiness, confusion) and have fast-acting carbohydrates available.

Adjustments and Monitoring

  • The doses of Lantus and Humalog may need to be adjusted based on the patient's response, with the goal of achieving target blood glucose levels while minimizing the risk of hypoglycemia.
  • The guidelines suggest increasing the basal insulin dose by 10% to 15%, or 2 to 4 units, once or twice weekly until the fasting blood glucose target is met 1.
  • Providers should consider decreasing the basal insulin dose by the same amount as the starting mealtime dose when advancing insulin therapy for patients not achieving HbA1c goals on optimally titrated basal insulin alone 1.

From the Research

Initial Dosages of Lantus and Humalog

To determine the initial dosages of Lantus (insulin glargine) and Humalog (insulin lispro) for a 94.8-pound patient to improve Hemoglobin A1C (HbA1c) levels, we need to consider the patient's weight and the typical dosage ranges for these insulins.

  • The patient's weight is 94.8 pounds, which is approximately 43 kg.
  • According to the study 2, the initial insulin dosage for patients with type 1 diabetes ranges from 0.25 to 1.0 U per kg per day.
  • For patients with type 2 diabetes, the initial insulin dosage is not explicitly stated in the provided studies, but it is often started at a lower dose and adjusted based on the patient's response.

Dosage Calculations

Based on the study 2, the initial dosage of Lantus (insulin glargine) could be calculated as follows:

  • 0.25 U/kg/day x 43 kg = 10.75 U/day (lower end of the range)
  • 1.0 U/kg/day x 43 kg = 43 U/day (upper end of the range)

For Humalog (insulin lispro), the dosage is typically adjusted based on the patient's mealtime glucose levels and insulin sensitivity.

  • The study 3 suggests that a twice-daily premixed insulin regimen (e.g., Humalog Mix 25/75) can provide better glycemic control than basal insulin alone.
  • The study 4 compares the efficacy of exenatide (a glucagon-like peptide-1 receptor agonist) with mealtime insulin lispro in patients with type 2 diabetes, but does not provide specific dosage recommendations for Humalog.

Summary of Findings

In summary, the initial dosages of Lantus and Humalog for a 94.8-pound patient to improve HbA1c levels are not explicitly stated in the provided studies. However, based on the study 2, the initial dosage of Lantus could be estimated to be between 10.75 U/day and 43 U/day, depending on the patient's individual needs and response to therapy. The dosage of Humalog would need to be adjusted based on the patient's mealtime glucose levels and insulin sensitivity, and may involve a twice-daily premixed insulin regimen or a basal/bolus regimen with Lantus and Humalog 3, 5.

Related Questions

How should I adjust the insulin regimen for a patient with Diabetes Mellitus (DM) on insulin glargine (glargine) 20 units in the morning and 15 units at night, and insulin lispro (lispro) 20 units three times a day (TID) at meal times, with a Hemoglobin A1C (HbA1C) level of 11%?
How to manage a patient with hyperglycemia on Metformin and Lantus with an HbA1c of 10.2%?
What is the best course of treatment for a 21-year-old female patient presenting with polydipsia (excessive thirst), fatigue, and dizziness, with a hemoglobin A1c (HbA1c) level indicating hyperglycemia?
What is the optimal insulin regimen for a 40-year-old female patient with uncontrolled diabetes (Diabetes Mellitus), a high Hemoglobin A1c (HbA1c) level of 11.6, and insulin resistance, currently taking Lantus (Insulin Glargine) 20 units at bedtime and Humalog (Insulin Lispro) three times a day before meals with a sliding scale, and also has hypothyroidism?
What is the best management plan for a patient with uncontrolled diabetes (HbA1c 10%) on hydrochlorothiazide (HCTZ), with potential diabetic retinopathy and normal CBC and lipid profiles?
What are the key signs and treatment approaches to differentiate between epididymoorchitis and testicular torsion?
What does an A1c (hemoglobin A1c) level of 12.2% and a c-peptide (connecting peptide) serum level <0.1 indicate for a 29-year-old male with type 1 diabetes?
What is the management for a patient with a prolonged QTc (corrected QT) interval?
What causes a prolonged QTc (corrected QT) interval?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.